Insider Buying: Perceptron, Inc. (NASDAQ:PRCP) Director Purchases 482991 Shares of Stock

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantum Capital Management boosted …

Perceptron logoPerceptron, Inc. (NASDAQ:PRCP) Director John F. Bryant purchased 482,991 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $2,294,207.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of PRCP traded down $0.08 during mid-day trading on Friday, hitting $4.06. 27,008 shares of the company’s stock were exchanged, compared to its average volume of 16,914. The firm has a market capitalization of $39.82 million, a P/E ratio of 10.41 and a beta of 1.01. Perceptron, Inc. has a 52 week low of $4.03 and a 52 week high of $12.00. The stock has a 50-day moving average of $4.46.

Perceptron (NASDAQ:PRCP) last released its quarterly earnings data on Thursday, May 9th. The scientific and technical instruments company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $15.63 million during the quarter, compared to analyst estimates of $18.40 million. Perceptron had a net margin of 2.61% and a return on equity of 3.45%. Equities research analysts predict that Perceptron, Inc. will post 0.13 EPS for the current fiscal year.

PRCP has been the subject of a number of research reports. ValuEngine cut Yext from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th. B. Riley set a $13.00 price target on shares of Audioeye and gave the stock a “buy” rating in a research note on Monday, May 13th. TheStreet raised shares of SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research note on Thursday, June 13th. Finally, Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantum Capital Management boosted its holdings in shares of Perceptron by 14.9% in the 4th quarter. Quantum Capital Management now owns 137,877 shares of the scientific and technical instruments company’s stock valued at $1,124,000 after buying an additional 17,887 shares during the last quarter. Penbrook Management LLC boosted its holdings in shares of Perceptron by 8.7% in the 1st quarter. Penbrook Management LLC now owns 173,993 shares of the scientific and technical instruments company’s stock valued at $1,305,000 after buying an additional 13,950 shares during the last quarter. Finally, Punch & Associates Investment Management Inc. boosted its holdings in shares of Perceptron by 3.4% in the 1st quarter. Punch & Associates Investment Management Inc. now owns 585,644 shares of the scientific and technical instruments company’s stock valued at $4,392,000 after buying an additional 19,060 shares during the last quarter. 71.20% of the stock is owned by institutional investors.

About Perceptron

Perceptron, Inc develops, produces, and sells various automated industrial metrology products and solutions to manufacturing organizations for dimensional gauging, dimensional inspection, and 3D scanning in Europe, Asia, and the Americas. It provides various in-line and near-line measurement solutions, including AutoGauge, AutoGauge ACF, AutoGuide, and Helix evo engineered metrology systems for industrial automated process control and assembly using fixed and robot mounted laser scanners; and offline measurement solutions comprising Coord3 and TouchDMIS for industrial gauging and dimensional inspection using standalone robot mounted laser scanners and coordinate measuring machines.

Featured Article: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Perceptron Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Perceptron and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Insider Selling: AtriCure Inc. (NASDAQ:ATRC) SVP Sells 10000 Shares of Stock

Quantum Capital Management increased its stake in shares of AtriCure by 0.7% during the 1st quarter. Quantum Capital Management now owns …

AtriCure logoAtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the senior vice president now owns 94,068 shares of the company’s stock, valued at $2,822,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ ATRC traded down $0.76 during trading hours on Friday, hitting $31.38. The company’s stock had a trading volume of 151,864 shares, compared to its average volume of 220,718. AtriCure Inc. has a 52 week low of $26.11 and a 52 week high of $36.49. The stock has a market capitalization of $1.23 billion, a P/E ratio of -33.38 and a beta of 0.27. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.37 and a quick ratio of 3.69. The company’s 50-day moving average price is $30.11.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. The business had revenue of $53.97 million for the quarter, compared to analysts’ expectations of $52.45 million. AtriCure had a negative net margin of 7.98% and a negative return on equity of 14.35%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) EPS. On average, research analysts anticipate that AtriCure Inc. will post -0.74 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Macquarie Group Ltd. increased its stake in AtriCure by 1.0% in the 4th quarter. Macquarie Group Ltd. now owns 65,786 shares of the medical device company’s stock valued at $2,013,000 after buying an additional 681 shares during the last quarter. Quantum Capital Management increased its stake in shares of AtriCure by 0.7% during the 1st quarter. Quantum Capital Management now owns 127,035 shares of the medical device company’s stock worth $3,403,000 after purchasing an additional 845 shares during the last quarter. Bell Rock Capital LLC purchased a new stake in shares of AtriCure during the 1st quarter worth approximately $26,000. Rhumbline Advisers increased its stake in shares of AtriCure by 3.4% during the 1st quarter. Rhumbline Advisers now owns 48,738 shares of the medical device company’s stock worth $1,306,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of AtriCure by 31.0% during the 4th quarter. Legal & General Group Plc now owns 6,958 shares of the medical device company’s stock worth $213,000 after purchasing an additional 1,646 shares during the last quarter. Hedge funds and other institutional investors own 89.28% of the company’s stock.

A number of analysts have commented on ATRC shares. JPMorgan Chase & Co. set a €78.00 ($90.70) price target on shares of Porsche Automobil and gave the company a “neutral” rating in a research report on Friday, April 12th. BTIG Research started coverage on shares of GrubHub in a research report on Tuesday, April 2nd. They set a “buy” rating and a $95.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price target (up previously from $115.00) on shares of Synopsys in a research report on Thursday, March 28th. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 4th. Finally, Zacks Investment Research cut shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Further Reading: What is the Beige Book?

Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Perceptron, Inc. (NASDAQ:PRCP) Insider Buys $22200.00 in Stock

Perceptron had a return on equity of 3.45% and a net margin of 2.61%. … Quantum Capital Management grew its position in shares of Perceptron by …

Perceptron logoPerceptron, Inc. (NASDAQ:PRCP) insider Valkenburg Richard Van bought 5,000 shares of Perceptron stock in a transaction dated Friday, June 14th. The stock was purchased at an average price of $4.44 per share, with a total value of $22,200.00. Following the completion of the purchase, the insider now owns 18,980 shares in the company, valued at $84,271.20. The purchase was disclosed in a filing with the SEC, which is available at this link.

Shares of Perceptron stock traded down $0.08 during mid-day trading on Friday, hitting $4.06. 27,008 shares of the stock were exchanged, compared to its average volume of 16,914. Perceptron, Inc. has a 12 month low of $4.03 and a 12 month high of $12.00. The firm’s 50-day moving average is $4.46. The stock has a market capitalization of $39.82 million, a P/E ratio of 10.41 and a beta of 1.01.

Perceptron (NASDAQ:PRCP) last posted its quarterly earnings results on Thursday, May 9th. The scientific and technical instruments company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Perceptron had a return on equity of 3.45% and a net margin of 2.61%. The company had revenue of $15.63 million during the quarter, compared to the consensus estimate of $18.40 million. Equities research analysts forecast that Perceptron, Inc. will post 0.13 EPS for the current fiscal year.

PRCP has been the subject of a number of analyst reports. B. Riley set a $13.00 price target on Audioeye and gave the company a “buy” rating in a research note on Monday, May 13th. TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research note on Thursday, June 13th. Zacks Investment Research downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Finally, ValuEngine downgraded Yext from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th.

A number of hedge funds have recently modified their holdings of the business. Punch & Associates Investment Management Inc. raised its holdings in Perceptron by 3.4% during the 1st quarter. Punch & Associates Investment Management Inc. now owns 585,644 shares of the scientific and technical instruments company’s stock valued at $4,392,000 after acquiring an additional 19,060 shares during the period. Quantum Capital Management grew its position in shares of Perceptron by 3.1% during the 1st quarter. Quantum Capital Management now owns 142,191 shares of the scientific and technical instruments company’s stock valued at $1,066,000 after purchasing an additional 4,314 shares in the last quarter. Finally, Penbrook Management LLC grew its position in shares of Perceptron by 8.7% during the 1st quarter. Penbrook Management LLC now owns 173,993 shares of the scientific and technical instruments company’s stock valued at $1,305,000 after purchasing an additional 13,950 shares in the last quarter. 71.20% of the stock is currently owned by institutional investors and hedge funds.

About Perceptron

Perceptron, Inc develops, produces, and sells various automated industrial metrology products and solutions to manufacturing organizations for dimensional gauging, dimensional inspection, and 3D scanning in Europe, Asia, and the Americas. It provides various in-line and near-line measurement solutions, including AutoGauge, AutoGauge ACF, AutoGuide, and Helix evo engineered metrology systems for industrial automated process control and assembly using fixed and robot mounted laser scanners; and offline measurement solutions comprising Coord3 and TouchDMIS for industrial gauging and dimensional inspection using standalone robot mounted laser scanners and coordinate measuring machines.

Featured Article: Depreciation

Receive News & Ratings for Perceptron Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Perceptron and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Quotient Ltd (NASDAQ:QTNT) Director Buys $27405.00 in Stock

Several hedge funds have recently added to or reduced their stakes in the business. Quantum Capital Management increased its position in shares of …

Quotient logoQuotient Ltd (NASDAQ:QTNT) Director Frederick Hallsworth acquired 3,150 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were bought at an average cost of $8.70 per share, with a total value of $27,405.00. Following the completion of the acquisition, the director now directly owns 74,398 shares in the company, valued at approximately $647,262.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Quotient stock traded up $0.43 during mid-day trading on Friday, hitting $10.49. The company’s stock had a trading volume of 376,184 shares, compared to its average volume of 362,449. The company has a current ratio of 4.59, a quick ratio of 3.98 and a debt-to-equity ratio of 72.27. The stock has a market cap of $669.73 million, a PE ratio of -5.46 and a beta of 0.88. The business has a 50 day moving average of $9.22. Quotient Ltd has a 12 month low of $5.52 and a 12 month high of $11.15.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings results on Tuesday, May 28th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.03. The business had revenue of $8.28 million during the quarter, compared to the consensus estimate of $7.30 million. Equities analysts forecast that Quotient Ltd will post -1.59 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the business. Quantum Capital Management increased its position in shares of Quotient by 0.7% in the first quarter. Quantum Capital Management now owns 388,302 shares of the company’s stock valued at $3,499,000 after acquiring an additional 2,744 shares during the period. Knott David M increased its position in shares of Quotient by 1.8% in the first quarter. Knott David M now owns 170,000 shares of the company’s stock valued at $1,532,000 after acquiring an additional 3,000 shares during the period. Lombard Odier Asset Management USA Corp increased its position in shares of Quotient by 4.0% in the first quarter. Lombard Odier Asset Management USA Corp now owns 260,000 shares of the company’s stock valued at $2,343,000 after acquiring an additional 10,000 shares during the period. Niemann Capital Management Inc. purchased a new position in shares of Quotient in the first quarter valued at about $101,000. Finally, Resources Investment Advisors Inc. purchased a new position in shares of Quotient in the first quarter valued at about $105,000. Hedge funds and other institutional investors own 63.91% of the company’s stock.

QTNT has been the subject of several recent research reports. ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Zacks Investment Research downgraded shares of Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Further Reading: QQQ ETF

Receive News & Ratings for Quotient Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quotient and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Perceptron, Inc. (NASDAQ:PRCP) Insider Valkenburg Richard Van Acquires 5000 Shares

Perceptron had a net margin of 2.61% and a return on equity of 3.45%. … Finally, Quantum Capital Management increased its position in Perceptron …

Perceptron logoPerceptron, Inc. (NASDAQ:PRCP) insider Valkenburg Richard Van purchased 5,000 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were purchased at an average cost of $4.44 per share, with a total value of $22,200.00. Following the completion of the purchase, the insider now owns 18,980 shares in the company, valued at approximately $84,271.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of PRCP traded down $0.08 during mid-day trading on Friday, reaching $4.06. The company’s stock had a trading volume of 27,008 shares, compared to its average volume of 16,914. The company has a fifty day moving average price of $4.46. The company has a market cap of $39.82 million, a P/E ratio of 10.41 and a beta of 1.01. Perceptron, Inc. has a 1 year low of $4.03 and a 1 year high of $12.00.

Perceptron (NASDAQ:PRCP) last released its earnings results on Thursday, May 9th. The scientific and technical instruments company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.13). Perceptron had a net margin of 2.61% and a return on equity of 3.45%. The business had revenue of $15.63 million during the quarter, compared to analysts’ expectations of $18.40 million. On average, analysts predict that Perceptron, Inc. will post 0.13 EPS for the current fiscal year.

PRCP has been the subject of a number of research reports. TheStreet raised SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research note on Thursday, June 13th. Zacks Investment Research downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th. B. Riley set a $13.00 price objective on Audioeye and gave the company a “buy” rating in a research report on Monday, May 13th. Finally, ValuEngine downgraded Yext from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 10th.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Punch & Associates Investment Management Inc. increased its stake in shares of Perceptron by 3.4% in the first quarter. Punch & Associates Investment Management Inc. now owns 585,644 shares of the scientific and technical instruments company’s stock worth $4,392,000 after acquiring an additional 19,060 shares during the last quarter. Penbrook Management LLC increased its stake in shares of Perceptron by 8.7% in the first quarter. Penbrook Management LLC now owns 173,993 shares of the scientific and technical instruments company’s stock worth $1,305,000 after acquiring an additional 13,950 shares during the last quarter. Finally, Quantum Capital Management increased its position in Perceptron by 3.1% during the first quarter. Quantum Capital Management now owns 142,191 shares of the scientific and technical instruments company’s stock worth $1,066,000 after buying an additional 4,314 shares during the last quarter. 71.20% of the stock is currently owned by institutional investors and hedge funds.

Perceptron Company Profile

Perceptron, Inc develops, produces, and sells various automated industrial metrology products and solutions to manufacturing organizations for dimensional gauging, dimensional inspection, and 3D scanning in Europe, Asia, and the Americas. It provides various in-line and near-line measurement solutions, including AutoGauge, AutoGauge ACF, AutoGuide, and Helix evo engineered metrology systems for industrial automated process control and assembly using fixed and robot mounted laser scanners; and offline measurement solutions comprising Coord3 and TouchDMIS for industrial gauging and dimensional inspection using standalone robot mounted laser scanners and coordinate measuring machines.

See Also: Straddles

Receive News & Ratings for Perceptron Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Perceptron and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts